Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest neutropenia Stories

2014-04-08 08:31:42

New submission based on positive Phase 3 data from the RESONATE(TM) trial RARITAN, N.J., April 8, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA(TM) (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. This regulatory submission is based on data from the Phase 3 RESONATE(TM) study in relapsed or refractory chronic...

2014-03-03 23:22:47

Researchers say reduced white blood cell count with chemotherapy could be corrected with appropriate medication. Raleigh, NC (PRWEB) March 03, 2014 Researchers examining the rates of grade 3 and 4 neutropenia, a side effect of chemotherapy, say patients who are younger than 65 are less likely to receive prophylactic treatment for the problem. Neutropenia is characterized by an abnormally low number of neutrophils, a type of circulating white blood cell that destroys bacteria in the blood....

2014-02-12 12:32:40

SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA((TM)) (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established.(1) IMBRUVICA is the first...

2013-12-10 16:25:09

-- Clinical Presentation in Waldenstrom's Macroglobulinemia Deemed "Best of ASH" -- NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA((TM))) at the 55(TH) Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including...

2013-11-14 12:54:05

New knowledge of drug mechanism paves road to new treatment approaches for patients suffering from frequent bacterial infections 1. Scientists at A*STAR’s Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.  A better understanding of...

2013-11-14 00:20:06

New knowledge of drug mechanism paves road to new treatment approaches for patients suffering from frequent bacterial infectionsSingapore, Nov 14, 2013 - (ACN Newswire) - Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a...

2013-05-16 16:25:39

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 31 - June 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "These studies reinforce Eisai's strong and growing commitment to oncology, particularly to...

2013-01-26 12:20:15

THOUSAND OAKS, Calif., Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta(® )(pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. FOLFOX and FOLFIRI are two of the most commonly used chemotherapy regimens for colorectal cancer. The study met its primary endpoint,...

2012-12-29 05:03:14

RnRMarketResearch.com adds “Chemotherapy Induced Neutropenia — Pipeline Review, H2 2012” new market research report to its store. Dallas, Texas (PRWEB) December 29, 2012 ℠Chemotherapy Induced Neutropenia — Pipeline Review, H2 2012“², provides an overview of the indication´s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features...

2012-12-19 16:24:02

GENEVA and WASHINGTON, Dec. 19, 2012 /PRNewswire-USNewswire/ -- This is our first task, caring for our children. It's our first job. If we don't get that right, we don't get anything right. That's how, as a society, we will be judged. (Obama 2012) "The Little Ambassador," Ariana-Leilani King-Pfeiffer is a 9-year-old dual German and American citizen, with only a German passport, currently living in Washington, DC. For four years her untreated life-threatening very rare blood and bone marrow...